Form 10-K CorMedix Inc. For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
CorMedix (CRMD) PT Lowered to $9 at RBC Capital
March 13, 2024 6:21 AM EDTRBC Capital analyst Gregory Renza lowered the price target on CorMedix (NASDAQ: CRMD) to $9.00 (from $10.00) while maintaining a Outperform rating.
The analyst comments "CRMD reported 4Q, with consistent messaging and incremental updates on launch & reimbursement strategy, into the reaffirmed proposed 4/15 inpatient launch, and... More
